I'm LongbridgeAI, I can summarize articles.AstraZeneca announced that its breast cancer drug Etcamah, when combined with Pfizer's Ibrance, failed to meet the primary endpoint of significantly delaying disease progression in a late-stage trial for advanced breast cancer. Although numerical improvements were observed, they lacked statistical significance. Safety data remained consistent with known profiles. This result follows recent FDA approval of Etcamah for a different indication based on separate trial results.
By Adria Calatayud
AstraZeneca said its new breast-cancer pill missed the key goal of slowing the disease from worsening in a late-stage clinical trial.
The U.K. drugmaker evaluated its Etcamah medicine, in combination with Pfizer's Ibrance, as a first-line treatment for patients with a type of advanced breast cancer that hadn't received any systemic treatment for advanced disease, it said late Friday.
The drug combination showed a numerical improvement in delaying signs that patients' cancer worsened compared with the standard therapy, but it wasn't enough to be considered statistically significant, AstraZeneca said.
Safety data were consistent with the known profile of each drug, it added.
The Etcamah trial results came a week after the U.S. Food and Drug Administration granted approval for the drug, based on the results of another trial, for advanced breast cancer upon the detection of a specific mutation. The company continues to study the pill in other trials, both as standalone therapy or in combination with other drugs.
"Early breast cancer represents an important opportunity, and we remain confident in the long-term potential of Etcamah in the early setting as we advance our broader program," AstraZeneca's executive vice president for oncology hematology research and development, Susan Galbraith, said.
AstraZeneca and partner Daiichi Sankyo separately said Monday that their Enhertu drug delivered benefits for patients with a form of advanced lung cancer in another late-stage study, leading to a six-month improvement in the time they lived without the disease worsening relative to the standard therapy.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
September 14, 2026 01:48 ET (05:48 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.